Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» hypertension
hypertension
Medtronic Finally Wins the Big One for Symplicity RDN Treatment
Medtronic Finally Wins the Big One for Symplicity RDN Treatment
Medical Devices and Diagnostics Industry
Medtronic
Medtech
Symplicity
FDA
renal denervation
hypertension
Flag link:
FDA Approves Renal Denervation for High Blood Pressure
FDA Approves Renal Denervation for High Blood Pressure
Medical Devices and Diagnostics Industry
Medtech
ReCor Medical
Paradise ultrasound renal denervation system
hypertension
renal denervation
Flag link:
Pharmacists treating hypertension patients could save US $1.1 trillion: Study
Pharmacists treating hypertension patients could save US $1.1 trillion: Study
Beckers Hospital Review
hypertension
pharmacists
Flag link:
Amgen’s Krystexxa lowers blood pressure in chronic gout trial
Amgen’s Krystexxa lowers blood pressure in chronic gout trial
Clinical Trials Arena
Amgen Krystexxa
gout
hypertension
clinical trials
Flag link:
Novo Nordisk, with coffers filling with cash, buys rival to Bayer's kidney drug Kerendia in $1.3B deal
Novo Nordisk, with coffers filling with cash, buys rival to Bayer's kidney drug Kerendia in $1.3B deal
Fierce Biotech
Novo Nordisk
KBP Biosciences
Bayer
chronic kidney disease
Kerendia
ocedurenone
hypertension
Flag link:
J&J sends blood pressure drug back to Idorsia
J&J sends blood pressure drug back to Idorsia
BioPharma Dive
Idorsia
JNJ
aprocitentan
hypertension
Flag link:
Hopes dim for Medtronic hypertension treatment after FDA panel rebuff
Hopes dim for Medtronic hypertension treatment after FDA panel rebuff
Medtech Dive
Medtronic
Medtech
hypertension
devices
FDA
Symplicity Spyral
Flag link:
Evaluating renal denervation rivals, FDA advisory panel backs ReCor, shuns Medtronic
Evaluating renal denervation rivals, FDA advisory panel backs ReCor, shuns Medtronic
Fierce Biotech
Medtech
FDA
renal denervation
Otsuka
Recor
Medtronic
hypertension
Flag link:
Recor wins FDA panel’s backing for high blood pressure device
Recor wins FDA panel’s backing for high blood pressure device
Medtech Dive
Recor
Medtech
renal denervation
hypertension
Flag link:
Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension
Roche, Alnylam Ink Potential $2.8B RNAi Partnership for Hypertension
BioSpace
Roche
Alnylam
RNAi
hypertension
zilebesiran
Flag link:
Windtree's hypertension med snarled in Catch-22 as hunt for partners comes up dry
Windtree's hypertension med snarled in Catch-22 as hunt for partners comes up dry
Fierce Biotech
Windtree Therapeutics
hypertension
rostafuroxin
Flag link:
Sky Labs publish findings on cuffless blood pressure measurement technology
Sky Labs publish findings on cuffless blood pressure measurement technology
Clinical Trials Arena
Sky Labs
South Korea
Medtech
hypertension
cuffless blood pressure measurement
Flag link:
Mineralys reports positive data from trial of lorundrostat for hypertension
Mineralys reports positive data from trial of lorundrostat for hypertension
Clinical Trials Arena
Mineralys Therapeutics
clinical trials
hypertension
lorundrostat
Flag link:
Sun Pharma issues recall for more than 34,000 bottles of blood pressure medication
Sun Pharma issues recall for more than 34,000 bottles of blood pressure medication
Endpoints
Sun Pharma
generics
product recalls
Diltiazem
hypertension
Flag link:
IPO Doors Creak Open as Mineralys Seeks $192M
IPO Doors Creak Open as Mineralys Seeks $192M
BioSpace
IPOs
Mineralys Therapeutics
hypertension
MLS-101
Flag link:
Mineralys polishes $100M IPO plans ahead of phase 3 in hypertension
Mineralys polishes $100M IPO plans ahead of phase 3 in hypertension
Fierce Biotech
IPOs
Mineralys
hypertension
Flag link:
Novartis to pay $245 mln to end antitrust cases over Exforge drug generics
Novartis to pay $245 mln to end antitrust cases over Exforge drug generics
Reuters
Novartis
generics
antitrust
legal
Exforge
hypertension
Flag link:
CinCor shares dive after blood pressure drug fails key trial
CinCor shares dive after blood pressure drug fails key trial
BioPharma Dive
CinCor Pharma
clinical trials
hypertension
baxdrostat
Flag link:
Months removed from a $118M Series B, Mineralys pushes ahead with PhII hypertension data
Months removed from a $118M Series B, Mineralys pushes ahead with PhII hypertension data
Endpoints
Mineralys
funding
MLS-101
hypertension
Flag link:
J&J, Idorsia plan filings for aprocitentan data in resistant hypertension
J&J, Idorsia plan filings for aprocitentan data in resistant hypertension
Pharmaphorum
JNJ
Idorsia
aprocitentan
hypertension
resistant hypertension
Flag link:
Pages
1
2
3
4
5
6
next ›
last »